Pneumococcal vaccination of older adults

References

• Austrian R, Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964; 60:759 - 76; http://dx.doi.org/10.7326/0003-4819-60-5-759; PMID: 14156606
   PubMed Web of Science ®Google Scholar
• Austrian R, Douglas RM, Schiffman G, Coetzee AM, Koornhof HJ, Hayden-Smith S, et al. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976; 89:184 - 94; PMID: 14433
   PubMedGoogle Scholar
• Fedson DS. Pneumococcal vaccination for older adults: the first 20 years. Drugs Aging 1999; 15:Suppl 1 21 - 30; http://dx.doi.org/10.2165/00002512-199915001-00003; PMID: 10690792
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012; 30:6802 - 8; http://dx.doi.org/10.1016/j.vaccine.2012.09.019; PMID: 23000122
   PubMed Web of Science ®Google Scholar
• Musher DM, Manoff SB, McFetridge RD, Liss CL, Marchese RD, Raab J, et al. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum Vaccin 2011; 7:919 - 28; http://dx.doi.org/10.4161/hv.7.9.15996; PMID: 21860256
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?. Lancet Infect Dis 2007; 7:597 - 606; http://dx.doi.org/10.1016/S1473-3099(07)70210-4; PMID: 17714673
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Bulkow LR, Singleton RJ, Nuorti JP, Hummel KB, Miernyk KM, et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine 2011; 29:2287 - 95; http://dx.doi.org/10.1016/j.vaccine.2011.01.029; PMID: 21255685
   PubMed Web of Science ®Google Scholar
• Dagan R, Givon-Lavi N, Greenberg D, Fritzell B, Siegrist CA. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 2010; 201:1570 - 9; http://dx.doi.org/10.1086/652006; PMID: 20384496
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009; 49:1318 - 25; http://dx.doi.org/10.1086/606046; PMID: 19814624
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al, Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32 - 41; http://dx.doi.org/10.1086/648593; PMID: 19947881
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011; 11:760 - 8; http://dx.doi.org/10.1016/S1473-3099(11)70090-1; PMID: 21621466
   PubMed Web of Science ®Google Scholar
• Flasche S, Slack M, Miller E. Long term trends introduce a potential bias when evaluating the impact of the pneumococcal conjugate vaccination programme in England and Wales. Euro Surveill 2011; 16:19868; PMID: 21616047
   PubMedGoogle Scholar
• Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine 2010; 28:4955 - 60; http://dx.doi.org/10.1016/j.vaccine.2010.05.030; PMID: 20576535
   PubMed Web of Science ®Google Scholar
• Evers SM, Ament AJ, Colombo GL, Konradsen HB, Reinert RR, Sauerland D, et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis 2007; 26:531 - 40; http://dx.doi.org/10.1007/s10096-007-0327-z; PMID: 17570001
   PubMed Web of Science ®Google Scholar
• Ament A, Fedson DS, Christie P. Pneumococcal vaccination and pneumonia: even a low level of clinical effectiveness is highly cost-effective. Clin Infect Dis 2001; 33:2078 - 9; http://dx.doi.org/10.1086/324356; PMID: 11700581
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH, van Hoek AJ, Fleming D, Trotter CL, Miller E, Edmunds WJ. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ 2012; 345:e6879; http://dx.doi.org/10.1136/bmj.e6879; PMID: 23103369
   PubMed Web of Science ®Google Scholar
• Musher DM, Sampath R, Rodriguez-Barradas MC. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence?. Clin Infect Dis 2011; 52:633 - 40; http://dx.doi.org/10.1093/cid/ciq207; PMID: 21292668
   PubMed Web of Science ®Google Scholar
• Musher DM. Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults?. Clin Infect Dis 2012; 55:265 - 7; http://dx.doi.org/10.1093/cid/cis364; PMID: 22495544
   PubMed Web of Science ®Google Scholar
• Doshi SM, Kulkarni PA, Liao JM, Rueda AM, Musher DM. The impact of statin and macrolide use on early survival in patients with pneumococcal pneumonia. Am J Med Sci 2013; 345:173 - 7; http://dx.doi.org/10.1097/MAJ.0b013e3182639c26; PMID: 23111390
   PubMed Web of Science ®Google Scholar